Article Correctness Is Author's Responsibility: Nature Gene Therapy publishes preclinical data of Ocugen’s OCU400 genetic modifier

(LaVoieHealthScience) Ocugen, Inc., a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced today the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases. OCU400 (NR2E3-AAV) has received two orphan drug designations.